Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Pharmaust Limited ( (AU:NUZ) ).
Neurizon Therapeutics has scheduled a shareholder webinar for 15 January 2026 to brief investors on the execution of recent funding initiatives, regulatory developments and upcoming operational milestones related to its participation in the HEALEY ALS Platform Trial. The event, led by CEO and Managing Director Dr Michael Thurn and other team members, will include a Q&A session, require prior registration, and will be recorded for later viewing, underscoring the company’s effort to increase transparency and engagement with investors as it advances its lead ALS drug candidate through key clinical and regulatory inflection points.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is an ASX-listed, clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative diseases. Its lead drug candidate, NUZ-001, is being developed for amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease, with a strategy aimed at accelerating patient access to effective ALS therapies while assessing NUZ-001’s potential in broader neurodegenerative indications through international collaborations and structured clinical programs.
Average Trading Volume: 640,986
Technical Sentiment Signal: Sell
Current Market Cap: A$65.53M
For a thorough assessment of NUZ stock, go to TipRanks’ Stock Analysis page.